SCHEMBL3380845

SCHEMBL3380845

Cc1[nH]c2c(Cl)ccc(C)c2c1CC(N)=O

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.57
CYP3A4 P08684 1/20 0.57
CYP2C19 P33261 1/20 0.57
ADRA2A P08913 1/20 0.43
CLCN2 P51788 1/20 0.43
KDM4E B2RXH2 2/20 0.38
MAPT P10636 2/20 0.38
MEN1 O00255 1/20 0.38
GAA P10253 1/20 0.38
KMT2A Q03164 1/20 0.38
SIRT1 Q96EB6 6/20 0.36
POLB P06746 1/20 0.35
CAPN1 P07384 1/20 0.34
CTSL P07711 1/20 0.34
CTSB P07858 1/20 0.34
CTSH P09668 1/20 0.34
P2RX7 Q99572 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4744827 0.88 CYP1A2 (0.73) CYP1A2CYP3A4CYP2C19KDM4EMAPT
SCHEMBL3381299 0.82 CYP1A2 (0.57) CYP1A2CYP3A4CYP2C19KDM4EMAPT
SCHEMBL3639386 0.82 CYP1A2 (0.57) CYP1A2CYP3A4CYP2C19ADRA2ACLCN2
SCHEMBL3639755 0.80 CYP1A2 (0.41) CYP1A2CYP3A4CYP2C19ADRA2ACLCN2
SCHEMBL3226447 0.77 KRAS (0.51) CYP1A2CYP3A4CYP2C19ADRA2ACLCN2
SCHEMBL3383227 0.77 MAPT (0.55) KDM4EMAPTMEN1GAAKMT2A
SCHEMBL13493974 0.75 CYP1A2 (0.44) CYP1A2CYP3A4CYP2C19ADRA2ACLCN2
SCHEMBL4558999 0.75 CYP1A2 (0.77) CYP1A2CYP3A4CYP2C19ADRA2ACLCN2
SCHEMBL3638375 0.73 CYP1A2 (0.45) CYP1A2CYP3A4CYP2C19ADRA2ACLCN2
SCHEMBL3802469 0.73 KDM4E (0.47) CYP1A2CYP3A4CYP2C19KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2149551-A1 N-(indol-3-ylalkyl)-(hetero)arylamid derivatives as modulators of EP2 receptors Bayer Schering Pharma AG (DE) 2010-02-03 EP claimed